Published by Josh White on 9th March 2022
(Sharecast News) - Renalytix announced the launch of the new 'myIntelX' provider access portal on Wednesday, to provide access for United States physicians to order 'KidneyIntelX' bioprognostic testing to identify type-2 diabetes patients at the greatest risk of rapid kidney disease progression.
URL: http://www.digitallook.com/dl/news/story/32519190/...